Kidney international · 2026
Anti-PLA2R1 IgG-mediated podocyte PLA2R1 cleavage drives glomerular subepithelial immune complex deposition in membranous nephropathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Wen-Bin, Hu Hai-Kun, Liu Wu, Rui Hong-Liang, Gao Chang, Geng Jie, Xu Jie, Dai Hao-Ran, Kuang Huang, Jia Ying-Min, Mao Jia-Rong, Huang Guang-Rui, Cui Zhao, Liu Bao-Li, Xu An-Long
Аннотация
INTRODUCTION: In membranous nephropathy (MN), subepithelial immune deposits and glomerular basement membrane (GBM) thickening are defining lesions, yet how circulating anti-phospholipase A2 receptor 1 (PLA2R1) IgG generates GBM-anchored complexes from podocyte antigen remains unclear.
METHODS: To clarify this, human podocytes stably expressing PLA2R1 and HEK293 cells expressing full-length or antibody-binding-deficient PLA2R1 (ΔN1-9) were stimulated with PLA2R1-positive MN [MN(P+)] serum or purified IgG or the metalloproteinase activator phorbol 12-myristate 13-acetate (PMA). Metalloprotease/γ-secretase dependence was tested with pharmacologic inhibitors; specificity controls included soluble ectodomain (ECD) blockade, IgG depletion, purified anti-PLA2R1 IgG, and THSD7A as unrelated antigen. Kidney biopsies underwent dual immunofluorescence and dual label immunogold electron microscopy. Recombinant ECD binding to collagen IV/laminin was assayed in vitro.
RESULTS: MN(P+) serum or purified anti-PLA2R1 IgG increased the PLA2R1 C-terminal fragment and soluble ECD. These effects were blocked by metalloproteinase ADAM10/17 inhibitors and by preincubating IgG/serum with soluble ECD and were complement-independent (heat-inactivation). MN(P+) IgG enhanced shedding of full-length PLA2R1 but not ΔN1-9, whereas PMA increased shedding of both, indicating epitope-dependent, antibody-triggered cleavage. MN(P+) IgG did not cleave THSD7A. In biopsies, PLA2R1-ECD was enriched within GBM deposits in MN(P+) only while PLA2R1-intracellular domain remained podocyte-restricted across groups. Quantitative electron microscopy confirmed GBM-biased ECD distribution in MN(P+). In vitro, PLA2R1-ECD bound collagen IV/laminin and selectively captured MN(P+) IgG. Early MN showed focal GBM thickening at deposit sites.
CONCLUSIONS: Anti-PLA2R1 IgG accelerates ADAM10/17-dependent shedding of podocyte PLA2R1 releasing ECD anchors to GBM constituents. This mechanism reconciles the serum antibody glomerular antigen match and the preferential localization of deposits.
METHODS: To clarify this, human podocytes stably expressing PLA2R1 and HEK293 cells expressing full-length or antibody-binding-deficient PLA2R1 (ΔN1-9) were stimulated with PLA2R1-positive MN [MN(P+)] serum or purified IgG or the metalloproteinase activator phorbol 12-myristate 13-acetate (PMA). Metalloprotease/γ-secretase dependence was tested with pharmacologic inhibitors; specificity controls included soluble ectodomain (ECD) blockade, IgG depletion, purified anti-PLA2R1 IgG, and THSD7A as unrelated antigen. Kidney biopsies underwent dual immunofluorescence and dual label immunogold electron microscopy. Recombinant ECD binding to collagen IV/laminin was assayed in vitro.
RESULTS: MN(P+) serum or purified anti-PLA2R1 IgG increased the PLA2R1 C-terminal fragment and soluble ECD. These effects were blocked by metalloproteinase ADAM10/17 inhibitors and by preincubating IgG/serum with soluble ECD and were complement-independent (heat-inactivation). MN(P+) IgG enhanced shedding of full-length PLA2R1 but not ΔN1-9, whereas PMA increased shedding of both, indicating epitope-dependent, antibody-triggered cleavage. MN(P+) IgG did not cleave THSD7A. In biopsies, PLA2R1-ECD was enriched within GBM deposits in MN(P+) only while PLA2R1-intracellular domain remained podocyte-restricted across groups. Quantitative electron microscopy confirmed GBM-biased ECD distribution in MN(P+). In vitro, PLA2R1-ECD bound collagen IV/laminin and selectively captured MN(P+) IgG. Early MN showed focal GBM thickening at deposit sites.
CONCLUSIONS: Anti-PLA2R1 IgG accelerates ADAM10/17-dependent shedding of podocyte PLA2R1 releasing ECD anchors to GBM constituents. This mechanism reconciles the serum antibody glomerular antigen match and the preferential localization of deposits.